New biomarkers identified by a research team in the Perelman School of Medicine at the University of Pennsylvania could help predict which Parkinson’s disease patients will suffer significant cognitive deficits within the first three years of their diagnosis. The results of the analysis from the international Parkinson’s Progression Markers Initiative (PPMI) are published this week in the open-access journal PLoS ONE. The findings are part of the Parkinson’s Progression Markers Initiative sponsored by The Michael J. Fox Foundation for Parkinson’s Research. Department co-investigators include Leslie Shaw, PhD, and John Trojanowski, MD, PhD.
Read the Department of Communications news release.